سعر اميبينيم/سيلاستاتين-كابي 500/500مجم 10 فيال وريد 20مل 2024

Imipenem 500 mg + cilastatin 500 mg powder for intravenous infusion, pack of 10 vials (20 ml vials); a carbapenem antibacterial with a renal dehydropeptidase inhibitor.

• Serious infections caused by susceptible bacteria: lower respiratory tract, urinary tract, intra-abdominal, gynecologic, bacterial septicemia, bone and joint, skin and skin structure infections, and endocarditis (not indicated for meningitis)DailyMed (U.S. National Library of Medicine)

• Most frequent in adults: phlebitis, nausea, diarrhea, vomiting, rash, injection-site pain, fever, hypotension and seizures.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Known hypersensitivity to any component of the product.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have occurred with beta-lactams; discontinue immediately if an allergic reaction occurs.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Seizures and other CNS reactions (confusion, myoclonic activity) have been reported; evaluate neurologically and reassess dose if they occur.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Co-administration with valproic acid/divalproex lowers valproate levels and increases breakthrough seizure risk; generally not recommended.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• GanciclovirGeneralized seizures reported; do not co-administer unless benefit outweighs risk.DailyMed (U.S. National Library of Medicine)
• ProbenecidIncreases imipenem plasma levels and half-life; not recommended.DailyMed (U.S. National Library of Medicine)
• Valproic acid / divalproex sodiumReduces valproic acid concentrations, risking breakthrough seizures; consider other antibacterials.DailyMed (U.S. National Library of Medicine)

• Available postmarketing data are insufficient to identify drug-associated risks of birth defects, miscarriage or adverse maternal/fetal outcomes.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Insufficient data on presence in human milk or effects on the breastfed child; weigh benefits of breastfeeding against maternal need.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Imipenem: Penem antibacterial that inhibits bacterial cell wall synthesis.
• Cilastatin: Inhibits renal dehydropeptidase, limiting the renal metabolism of imipenem.